Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab.
- Author:
Wei-Jun GU
1
;
Wei XU
;
Si-Xuan QIAN
;
Yu-Jie WU
;
Ming HONG
;
Li-Juan CHEN
;
Han-Xin WU
;
Hua LU
;
Hong-Xia QIU
;
Jian-Yong LI
Author Information
1. Department 0f Hematology, The First Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Clinical Trial
- MeSH:
Adult;
Aged;
Antibodies, Monoclonal;
administration & dosage;
Antibodies, Monoclonal, Murine-Derived;
Antineoplastic Agents;
administration & dosage;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Cyclophosphamide;
administration & dosage;
Female;
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell;
drug therapy;
Male;
Middle Aged;
Remission Induction;
Rituximab;
Vidarabine;
administration & dosage;
analogs & derivatives
- From:
Journal of Experimental Hematology
2008;16(4):938-942
- CountryChina
- Language:Chinese
-
Abstract:
In order to evaluate the efficiency of rituximab combined with fludarabine, cyclophosphamide and rituximab (FCR) regimen for chronic lymphocytic leukemia (CLL). Five patients with CLL were treated with FCR regimen for 2 - 6 courses. FCR regimen included fludarabine 25 mg/m(2) via intravenous drip at day 2 - 4, cyclophosphamide 250 mg/m(2) via intravenous drip at day 2 - 4 and rituximab 375 mg/m(2) via intravenous drip at day 1. Courses were repeated every 4 weeks. Minimal residual disease (MRD) was determined by multiparametic flow cytometry. The results showed that three patients achieved complete remission, 2 patients achieved partial remission. MRD was negative in two patients. In conclusion, FCR is an effective therapeutic regimen for treating CLL patients and is worth to be used in clinic.
